Overview

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

Status:
Recruiting

Trial end date:
2022-06-18

Target enrollment:

Participant gender:

Summary

This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Andrei Iagaru
Stanford University

Collaborator:

General Electric

Treatments:

Bombesin
Estrogens
Gastrin-Releasing Peptide